WO2025012900 - GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY
National phase entry:
Publication Number
WO/2025/012900
Publication Date
16.01.2025
International Application No.
PCT/IL2024/050670
International Filing Date
09.07.2024
Title **
[English]
GENETICALLY ENGINEERED MUCOSAL-ASSOCIATED INVARIANT T (MAIT) CELLS FOR ADOPTIVE TRANSFER CELLTHERAPY
[French]
CELLULES T INVARIANTES ASSOCIÉES AUX MUQUEUSES (MAIT) GÉNÉTIQUEMENT MODIFIÉES POUR THÉRAPIE CELLULAIRE PAR TRANSFERT ADOPTIF
Applicants **
PLURI BIOTECH LTD.
HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD.
Inventors
MACHLENKIN, Arthur
LOTEM, Michal
SHAKED, Helena Lea
KLEIN SILBERMAN, Shira
Priority Data
63/525,836
10.07.2023
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
ILPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3465 | |
| EPO | Filing, Examination, Granting | 27674 | |
| Japan | Filing, Examination, Granting | 3021 | |
| South Korea | Filing, Examination, Granting | 3857 | |
| USA | Filing, Examination, Granting | 11990 |
Total:
50,007
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates in general to the field of genetic engineering of immune cells, specifically to mucosal-associated invariant T (MAIT) cells genetically engineered to express an exogeneous T cell receptor (TCR) and uses thereof. More specifically, the invention in embodiments thereof relates to cell compositions adapted for adoptive transfer cell therapy (ACT) providing for improved therapeutic modalities.[French]
La présente invention concerne en général le domaine de l'ingénierie génétique de cellules immunitaires, en particulier des cellules T invariantes associées aux muqueuses (MAIT) génétiquement modifiées pour exprimer un récepteur de lymphocytes T (TCR) exogène et leurs utilisations. Plus spécifiquement, l'invention concerne, dans certains modes de réalisation, des compositions cellulaires conçues pour une thérapie cellulaire par transfert adoptif (ACT) permettant d'obtenir des modalités thérapeutiques améliorées.